Clinical Study of Divozilimab in Patients With Systemic Scleroderma | MicrobiomeTrials← Back to trialsNCT05726630
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2022-12-26Est. Completion: 2024-10-01
Enrollment target: 152 participants Locations- Chelyabinsk Regional Clinical hospital, Chelyabinsk, Russia
- Clinical Rheumatology Hospital №25, Saint Petersburg, Russia
- North-Western state Medical University named after I.I. Mechnikov, Saint Petersburg, Russia
Other microbiome trials you might be interested in
Systemic Sclerosis
In the current study we aim to assess the macrovascular involvement in SSc patients through an ultrasound (US) evaluatio…
Asyut, EgyptCompleted Mar 1, 2025
Autoimmune Diseases
Background:
Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause t…
Bethesda, United StatesEst. completion Apr 22, 2030